Marni B. McClure

Marni B. McClure

Auto-generated profile, based on publicly available information

Marni B. McClure

Division of Molecular Oncology, National Cancer Center Research Institute, Tokyo, 104-0045, Japan

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 April 2020 in Nature
Verified
Journal Article
Closed access
PDF file
YSYuki Saito
Yuki Saito
JKJunji Koya
Junji Koya
MAMitsugu Araki
Mitsugu Araki
YKYasunori Kogure
Yasunori Kogure
SSSumito Shingaki
Sumito Shingaki
KKKeisuke Kataoka
Keisuke Kataoka

17 February 2022 in Blood
Verified
Journal Article
Open access
PDF file
YKYasunori Kogure
Yasunori Kogure
TKTakuro Kameda
Takuro Kameda
JKJunji Koya
Junji Koya
MYMakoto Yoshimitsu
Makoto Yoshimitsu
KNKisato Nosaka
Kisato Nosaka
KKKeisuke Kataoka
Keisuke Kataoka
Adult T-cell leukemia/lymphoma (ATL) is an aggressive neoplasm immunophenotypically resembling regulatory T cells, associated with human T-cell leukemia virus type-1. Here, we performed whole-genome sequencing (WGS) of 150 ATL cases to reveal the overarching landscape of genetic alterations in ATL. We discovered frequent (33%) loss-of-function alterations preferentially targeting the CIC long isoform, which were overlooked by previous exome-centric studies of various cancer types. Long but not short isoform–specific inactivation of Cic selectively increased CD4+CD25+Foxp3+ T cells in vivo. We also found recurrent (13%) 3′-truncations of REL, which induce transcriptional upregulation and generate gain-of-function proteins. More importantly, REL truncations are also common in diffuse large B-cell lymphoma, especially in germinal center B-cell–like subtype (12%). In the non-coding genome, we identified recurrent mutations in regulatory elements, particularly splice sites, of several driver genes. In addition, we characterized the different mutational processes operative in clustered hypermutation sites within and outside immunoglobulin/T-cell receptor genes and identified the mutational enrichment at the binding sites of host and viral transcription factors, suggesting their activities in ATL. By combining the analyses for coding and noncoding mutations, structural variations, and copy number alterations, we discovered 56 recurrently altered driver genes, including 11 novel ones. Finally, ATL cases were classified into 2 molecular groups with distinct clinical and genetic characteristics based on the driver alteration profile. Our findings not only help to improve diagnostic and therapeutic strategies in ATL, but also provide insights into T-cell biology and have implications for genome-wide cancer driver discovery.

13 July 2021 in Blood Cancer Discovery
Verified
Journal Article
Open access
PDF file
JKJunji Koya
Junji Koya
YSYuki Saito
Yuki Saito
TKTakuro Kameda
Takuro Kameda
YKYasunori Kogure
Yasunori Kogure
MYMitsuhiro Yuasa
Mitsuhiro Yuasa
KKKeisuke Kataoka
Keisuke Kataoka
Premalignant clonal expansion of human T-cell leukemia virus type-1 (HTLV-1)–infected cells occurs before viral carcinogenesis. Here we characterize premalignant cells and the multicellular ecosystem in HTLV-1 infection with and without adult T-cell leukemia/lymphoma (ATL) by genome sequencing and single-cell simultaneous transcriptome and T/B-cell receptor sequencing with surface protein analysis. We distinguish malignant phenotypes caused by HTLV-1 infection and leukemogenesis and dissect clonal evolution of malignant cells with different clinical behavior. Within HTLV-1–infected cells, a regulatory T-cell phenotype associates with premalignant clonal expansion. We also delineate differences between virus- and tumor-related changes in the nonmalignant hematopoietic pool, including tumor-specific myeloid propagation. In a newly generated conditional knockout mouse model recapitulating T-cell–restricted CD274 (encoding PD-L1) gene lesions found in ATL, we demonstrate that PD-L1 overexpressed by T cells is transferred to surrounding cells, leading to their PD-L1 upregulation. Our findings provide insights into clonal evolution and immune landscape of multistep virus carcinogenesis. Significance: Our multimodal single-cell analyses comprehensively dissect the cellular and molecular alterations of the peripheral blood in HTLV-1 infection, with and without progression to leukemia. This study not only sheds light on premalignant clonal expansion in viral carcinogenesis, but also helps to devise novel diagnostic and therapeutic strategies for HTLV-1–related disorders. This article is highlighted in the In This Issue feature, p. 403

1 October 2018 in JAAD Case Reports
Verified
Journal Article
Open access
RBRachel Chikowski Byrd
Rachel Chikowski Byrd
KMKimberly J. Mournighan
Kimberly J. Mournighan
MBMichael Baca-Atlas
Michael Baca-Atlas
MHMargaret R. Helton
Margaret R. Helton
NSNatalie Z. Sun
Natalie Z. Sun
MSMarni B. Siegel
Marni B. Siegel

16 April 2020 in PLOS Biology
Verified
Journal Article
Open access
PDF file
MMMarni B. McClure
Marni B. McClure
KHKacey C. Hall
Kacey C. Hall
EBErin F. Brooks
Erin F. Brooks
CACatherine T. Allen
Catherine T. Allen
KLKenneth S. Lyle
Kenneth S. Lyle
Encouragement of students across all communities through scientific outreach programs is critical to engaging the next generation, exciting young minds to pursue careers in science and medicine. Herein, we present a uniquely structured and widely influential science outreach program. Founded in 2005, the Duke Chemistry Outreach (DCO) employs a pedagogical approach to outreach that aims to teach its audience a new scientific concept, while instilling a pure enjoyment of science. DCO has performed 583 events reaching over 70,000 participants throughout 2,270 hours, with the majority of events in Durham, the surrounding North Carolinian communities, and across 8 other states. The flexibility and diversity of this outreach program creates a framework amendable for others to adopt in both secondary and higher education settings.

1 May 2019 in Neuro-Oncology Advances
Verified
Journal Article
Open access
PDF file
MSMaria J Sambade
Maria J Sambade
ASAmanda E D Van Swearingen
Amanda E D Van Swearingen
MMMarni B McClure
Marni B McClure
ADAllison M Deal
Allison M Deal
CSCharlene Santos
Charlene Santos
CACarey K Anders
Carey K Anders
Despite the poor prognosis of triple negative breast cancer (TNBC) brain metastases, there are no approved systemic therapies. We explored the DNA-damaging Poly(ADP-ribose) polymerase (PARP) inhibitor (PARPi) niraparib in intracranial mouse models of BRCA-mutant TNBC. Mice bearing intracranial human-derived TNBC cell lines (SUM149, MDA-MB-231Br, or MDA-MB-436) were treated with niraparib and monitored for survival; intracranial tissues were analyzed for PAR levels and niraparib concentration by mass spectrometry. RNASeq data of primary breast cancers using The Cancer Genome Atlas was analyzed for DNA damage signatures. Combined RAD51 and PARP inhibition in TNBC cell lines were assessed in vitro by colony forming assays. Daily niraparib increased median survival and decreased tumor burden in the BRCA-mutant MDA-MB-436 model, but not in the BRCA-mutant SUM149 or BRCA-wild-type MDA-MB-231Br models despite high concentrations in intracranial tumors. RAD51 inhibitor B02 was shown to sensitize all cell lines to PARP inhibition. In analysis of BRCA-mutant primary human TNBCs, gene expression predictors of PARPi sensitivity and DNA repair signatures demonstrate widespread heterogeneity, which may explain the differential response to PARPi. Interestingly, these signatures are significantly correlated to RAD51 expression including PARPi sensitivity (R2 = 0.602, R2= 0.758). Niraparib penetrates intracranial tumor tissues in mouse models of TNBC with impressive single-agent efficacy in BRCA-mutant MDA-MB-436. Clinical evaluation of niraparib to treat TNBC brain metastases, an unmet clinical need desperate for improved therapies, is warranted. Further compromising DNA repair through RAD51 inhibition may further augment TNBC’s response to PARPi.